Zydus Lifesciences (ZYDUSLIFE) Fundamentals 2026 — P/E 22.5x, Revenue Analysis | SniperIQ
Zydus Lifesciences (ZYDUSLIFE) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1.13 Lakh Crore, trading at ₹1129.75 on the BSE. This SniperIQ fundamentals page covers Zydus Lifesciences's valuation (P/E 22.5x, P/B 4.2x), profitability (net margin 18.6%), revenue (₹27,148 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zydus Lifesciences's market cap?
Zydus Lifesciences (ZYDUSLIFE) has a market capitalization of approximately ₹1.13 Lakh Crore, trading at ₹1129.75 on the BSE. Market cap moves with the live share price.
What is Zydus Lifesciences's P/E ratio?
Zydus Lifesciences's trailing twelve-month P/E ratio is 22.5x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zydus Lifesciences?
Zydus Lifesciences runs a net profit margin of 18.6%, a gross margin of 56.3%, and an operating margin of 28.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zydus Lifesciences generate?
Zydus Lifesciences reported revenue of ₹27,148 Crore for fiscal year 2026, with net income of ₹5,040 Crore and earnings per share (EPS) of 50.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zydus Lifesciences pay a dividend?
Zydus Lifesciences offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zydus Lifesciences financially healthy?
Zydus Lifesciences carries a debt-to-equity ratio of 0.46x and a current ratio of 1.27x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zydus Lifesciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zydus Lifesciences (ZYDUSLIFE) the key facts are: market cap ₹1.13 Lakh Crore, P/E 22.5x, revenue ₹27,148 Crore, 52-week range 835.85-1181. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zydus Lifesciences's full fundamentals live
Get Zydus Lifesciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.